TwinStrand Biosciences utilizes Duplex Sequencing technology to accurately identify ultra-low frequency genomic variants that conventional next-generation sequencing methods cannot detect. This high-resolution approach significantly reduces sequencing error rates, enabling precise insights for applications such as residual cancer detection and genetic toxicology.
Funding
$82.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Conventional next-generation sequencing (NGS) methods often struggle to accurately detect ultra-low frequency genomic variants due to inherent sequencing errors. This limitation hinders precise insights in applications like residual cancer detection, mutation signature analysis, and genetic toxicology assessments. Standard NGS error rates can obscure rare but significant mutations, leading to inaccurate results.
Solution
TwinStrand Biosciences addresses this challenge with its Duplex Sequencing technology, which reduces sequencing error rates from 1-in-100 to 1-in-10 million. This enhanced accuracy enables the detection of rare variants that are otherwise undetectable by standard NGS methods. The technology employs a combination of proprietary biochemistry and cloud-based informatics to independently track both strands of individual DNA molecules, comparing the results to eliminate errors. TwinStrand provides off-the-shelf kits and custom assay development for specific research needs, including measurable residual disease (MRD) detection and mutagenesis studies.
Target Audience
The primary audience includes researchers and scientists in fields such as oncology, genetic toxicology, and drug development who require highly accurate detection of low-frequency genomic variants.
Features
- Duplex Sequencing technology that reduces sequencing error rates to 1 in 10 million
- Proprietary biochemistry for accurate DNA strand tracking
- Cloud-based informatics for error elimination and variant calling
- Off-the-shelf kits for AML MRD detection and mutagenesis assays
- Custom assay development services for specific research applications
- Identifies genomic features that determine susceptibility to benzo(a)pyrene-induced _in vivo_ mutations